KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Inventory (2017 - 2025)

Historic Change in Inventory for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $28.8 million.

  • BeOne Medicines' Change in Inventory rose 22097.16% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.0 million, marking a year-over-year increase of 134.77%. This contributed to the annual value of $91.5 million for FY2024, which is 3508.53% down from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Change in Inventory is $28.8 million, which was up 22097.16% from -$2.2 million recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Change in Inventory peaked at $91.6 million during Q4 2021, and registered a low of -$23.8 million during Q3 2024.
  • For the 5-year period, BeOne Medicines' Change in Inventory averaged around $24.5 million, with its median value being $28.6 million (2022).
  • Over the last 5 years, BeOne Medicines' Change in Inventory had its largest YoY gain of 135752.95% in 2021, and its largest YoY loss of 745090.09% in 2021.
  • Over the past 5 years, BeOne Medicines' Change in Inventory (Quarter) stood at $91.6 million in 2021, then tumbled by 120.67% to -$18.9 million in 2022, then surged by 567.6% to $88.6 million in 2023, then dropped by 10.38% to $79.4 million in 2024, then tumbled by 63.68% to $28.8 million in 2025.
  • Its Change in Inventory was $28.8 million in Q3 2025, compared to -$2.2 million in Q2 2025 and -$4.0 million in Q1 2025.